Please use this identifier to cite or link to this item:
Title: Cost-effectiveness of insulin degludec versus insulin glargine U100 in patients with type 1 and type 2 diabetes in Portugal: evidence from SWITCH 1&2 trials
Author: Darbà, Josep
Ascanio, Meritxell
Carvalho, Davide
Conde, Vasco
Pedersen, Kasper S.
Keywords: Anàlisi cost-benefici
Salut pública
Cost effectiveness
Public health
Issue Date: 20-Dec-2019
Publisher: Cortex - Publicacoes Tecnicas e Cientificas
Abstract: Objectives: To assess the cost-effectiveness of insulin degludec (degludec) versus insulin glargine (glargine) U100 from a Portuguese healthcare perspective using data from SWITCH 1 & 2 trials. - - - Methods: A short-term model estimated cost-effectiveness of degludec versus glargine U100 in type 1 diabetes (T1DM) basal bolus (B/B) and type 2 diabetes (T2DM) basal oral therapy (BOT) patients. The model captured hypoglycaemia rates and insulin dosing. Clinical outcomes were obtained from SWITCH 1 & 2. Disutilities related to hypoglycaemic events and insulin, needles and blood glucose tests costs were also included. Benefits were measured in QALYs. One-way and probabilistic sensitivity analyses were conducted (...)
Note: Versió postprint del document publicat a:
It is part of: Revista Portuguesa de Diabetes, 2019, vol. 14, num. 4, p. 141-150
ISSN: 1646-3439
Appears in Collections:Articles publicats en revistes (Economia)

Files in This Item:
File Description SizeFormat 
695776.pdf540.18 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons